Synonyms: GW679769 | Rezonic (proposed trade name) | Zunrisa (proposed trade name)
Compound class:
Synthetic organic
Comment: Casopitant is an investigational NK1 receptor antagonist.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Casopitant has completed Phase 2I clinical trials evaluating its utility as an antiemetic for the treatment of chemotherapy-induced nausea and vomiting. Phase 2 clinical trials for insomnia, major depressive disorder (MDD) and anxiety disorders have also been completed. Click here to link to ClinicalTrials.gov's complete list of casopitant trials, and here to link to GSK's list of clinical trials evaluating this compound (hosted on the GSK clinical study register). |